Angiogenesis Inhibitors: all 4,430 studies that test it

Page 9 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid TumorsTerminatedNCT02597036Phase 1Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• Role of Intravitreal Aflibercept Injection for the Treatment of Radiation MaculopathyCompletedNCT02586727Phase 2Results posted
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or RectumCompletedNCT02582970Phase 4Results posted
• Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.CompletedNCT02581995Phase 4Results posted
• Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the EyeCompletedNCT02581891Phase 4Results posted
• Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic CancerCompletedNCT02581215Phase 2Results posted
• Head to Head Study of Anti-VEGF Treatment.CompletedNCT02577107Phase 4Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsCompletedNCT02564198Phase 1Results posted
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/2Results posted
• Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
• Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or BevacizumabCompletedNCT02559180Phase 4Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisCompletedNCT02545907Phase 1/2Results posted
• A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedNCT02541383Phase 3Results posted
• Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT02540954Phase 3Results posted
• A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02539225Phase 2Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid TumorsCompletedNCT02525536Phase 1Results posted
• Lenalidomide for Adult Histiocyte DisordersActive, not recruitingNCT02523040Phase 2Results posted
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by SurgeryCompletedNCT02520141Phase 2Results posted
• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedNCT02516423Phase 3Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric CancerCompletedNCT02514551Phase 2Results posted
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular DegenerationCompletedNCT02510794Phase 2Results posted
• Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165CompletedNCT02507336Phase 2Results posted
• Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVOCompletedNCT02503540Phase 4Results posted
• Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain MetastasesTerminatedNCT02490878Phase 2Results posted
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT02484690Phase 2Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular EdemaCompletedNCT02471651Phase 4Results posted
• IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMDCompletedNCT02462889Phase 2Results posted
• Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeCompletedNCT02456857Phase 2Results posted
• The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid ExudatesCompletedNCT02448446Phase 1/2Results posted
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results posted
• Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT02446236Phase 1Results posted
• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) CancerCompletedNCT02443883Phase 2Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-FetoproteinCompletedNCT02435433Phase 3Results posted
• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerCompletedNCT02426125Phase 3Results posted
• Optimising Renal Outcome in Myeloma Renal FailureCompletedNCT02424851Phase 2Results posted
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)CompletedNCT02420821Phase 3Results posted
• Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)TerminatedNCT02418754Phase 2Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
• CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedNCT02401815Phase 1/2Results posted
• Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2Results posted
• TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory ChoriocarcinomaCompletedNCT02396511Phase 2Results posted
• Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsCompletedNCT02396316Phase 3Results posted
• Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCCompletedNCT02394795Phase 3Results posted
• Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of PrematurityCompletedNCT02390531Phase 1Results posted
• Intranasal Bevacizumab for HHT-Related EpistaxisCompletedNCT02389959Phase 4Results posted
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
• Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal CancersCompletedNCT02384759Phase 2Results posted
• RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of PrematurityCompletedNCT02375971Phase 3Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
• Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula EdemaCompletedNCT02366468Phase 4Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02366143Phase 3Results posted
• Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DMECompletedNCT02363621Phase 2Results posted
• Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT02358889Phase 2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular EdemaCompletedNCT02348918Phase 2Results posted
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:CompletedNCT02348008Phase 1/2Results posted
• A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)TerminatedNCT02343549Phase 2Results posted
• TH-302 in Combination With Bevacizumab for GlioblastomaCompletedNCT02342379Phase 2Results posted
• Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
• Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal CancerCompletedNCT02340949Phase 2Results posted
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedNCT02330562Phase 1/2Results posted
• Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)CompletedNCT02322320Phase 3Results posted
• Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerCompletedNCT02317991Phase 2Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach CancerCompletedNCT02314117Phase 3Results posted
• Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade GliomasCompletedNCT02313272Phase 1Results posted
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted
• Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell LymphocytosisTerminatedNCT02309515Phase 2Results posted
• Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular DegenerationCompletedNCT02305238Phase 4Results posted
• Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME TrialCompletedNCT02299336Phase 4Results posted
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT02292758Phase 2Results posted
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results posted
• 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results posted
• Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaCompletedNCT02285062Phase 3Results posted
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease PatientsCompletedNCT02273596Phase 2Results posted
• Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung CancerCompletedNCT02272413Phase 3Results posted
• A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) PatientsCompletedNCT02259088Phase 3Results posted
• Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02257632Phase 4Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
• Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2Results posted
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasCompletedNCT02213913Phase 1/2Results posted
• PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionCompletedNCT02213289Phase 2Results posted
• Bevacizumab Against Recurrent Retinal DetachmentCompletedNCT02192970Phase 2Results posted

← Angiogenesis Inhibitors overview